User profiles for John A Snowden
Professor John SnowdenSheffield Teaching Hospitals NHS Foundation Trust & University of Sheffield, Sheffield, UK Verified email at ebmt.org Cited by 18329 |
[PDF][PDF] Guidelines for the diagnosis and management of adult aplastic anaemia
…, G Mufti, JA Snowden… - British journal of …, 2016 - redbook.streamliners.co.nz
… Mufti,7 John A. Snowden,8 Sujith Samarasinghe,9 Anna Wood, BCSH Task Force
Member10 and Judith CW Marsh7 on behalf of the British Society for Standards in Haematology …
Member10 and Judith CW Marsh7 on behalf of the British Society for Standards in Haematology …
[HTML][HTML] Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years
…, M Mohty, R Peffault de Latour, JA Snowden… - Bone marrow …, 2021 - nature.com
Numbers of Hematopoietic cell transplantation (HCT) in Europe and collaborating countries
continues to rise with 48,512 HCT in 43,581 patients, comprising of 19,798 (41%) allogeneic …
continues to rise with 48,512 HCT in 43,581 patients, comprising of 19,798 (41%) allogeneic …
[HTML][HTML] Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
JA Snowden, I Sánchez-Ortega… - Bone marrow …, 2022 - nature.com
For over two decades, the EBMT has updated recommendations on indications for haematopoietic
cell transplantation (HCT) practice based on clinical and scientific developments in …
cell transplantation (HCT) practice based on clinical and scientific developments in …
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
…, M Raghavan, M Cook, JA Snowden… - Blood, The Journal …, 2012 - ashpublications.org
Strategies that augment a GVL effect without increasing the risk of GVHD are required to
improve the outcome after allogeneic stem cell transplantation (SCT). Azacitidine (AZA) up-…
improve the outcome after allogeneic stem cell transplantation (SCT). Azacitidine (AZA) up-…
[PDF][PDF] Guidelines for the diagnosis and management of multiple myeloma 2011
JM Bird, RG Owen, S d'Sa, JA Snowden… - British journal of …, 2011 - iacld.com
… ’ and ‘Supportive care in multiple myeloma 2011’ (Snowden et al 2011). They are designed
to … of peripheral neuropathy is described in detail in the supportive care guideline (Snowden …
to … of peripheral neuropathy is described in detail in the supportive care guideline (Snowden …
Inhibiting Dickkopf‐1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma
…, HR Evans, JA Snowden… - Journal of Bone and …, 2009 - academic.oup.com
Multiple myeloma (MM) is associated with the development of osteolytic bone disease,
mediated by increased osteoclastic bone resorption and impaired osteoblastic bone formation. …
mediated by increased osteoclastic bone resorption and impaired osteoblastic bone formation. …
[HTML][HTML] The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their …
…, J Murray, R Peffault de Latour, JA Snowden… - Bone marrow …, 2020 - nature.com
The new coronavirus SARS-CoV-2 has rapidly spread over the world causing the disease
by WHO called COVID-19. This pandemic poses unprecedented stress on the health care …
by WHO called COVID-19. This pandemic poses unprecedented stress on the health care …
Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019
…, A Nagler, R Peffault de Latour, JA Snowden… - Bone marrow …, 2019 - nature.com
This is the seventh special EBMT report on the indications for haematopoietic stem cell
transplantation for haematological diseases, solid tumours and immune disorders. Our aim is to …
transplantation for haematological diseases, solid tumours and immune disorders. Our aim is to …
Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting …
…, R Balabanov, J Burman, B Sharrack, JA Snowden… - Jama, 2019 - jamanetwork.com
Importance Hematopoietic stem cell transplantation (HSCT) represents a potentially useful
approach to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS…
approach to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS…
[HTML][HTML] Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood …
…, R Saccardi, F Sanchez-Guijo, JA Snowden… - …, 2020 - ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which
autologous or allogeneic T cells are engineered to express a CAR targeting a membrane …
autologous or allogeneic T cells are engineered to express a CAR targeting a membrane …